Acts of Parliament assented to – Act Nos 32 to 40 of 2026

Overview

The Commonwealth Parole Board Act 2026 was enacted by the Australian Parliament to address the need for a more structured and fair parole decision-making process. This Act was assented to on 8 April 2026, establishing the Commonwealth Parole Board as an independent body responsible for assessing and making parole decisions for certain federal offenders. The policy objective of this Act is to ensure that parole decisions are made in a consistent, transparent, and fair manner, thereby improving the integrity of the parole process and enhancing public confidence in the criminal justice system. The establishment of the Commonwealth Parole Board aims to provide a more systematic and evidence-based approach to parole, addressing previous criticisms of inconsistent and arbitrary parole decisions.

Scope and Application

The Commonwealth Parole Board Act 2026 establishes the Commonwealth Parole Board and outlines its jurisdiction and functions. This legislation applies to individuals who are serving sentences in federal prisons, thereby providing a framework for parole decisions that affect these prisoners. The Act provides for the establishment of the Board, its composition, and its powers and functions, which include making parole decisions and supervising the release of prisoners on parole. The Act applies across the Commonwealth of Australia and is intended to ensure a uniform approach to parole decisions. The scope of the Act is further extended through subordinate instruments, which may provide additional details on the operational aspects of the Board and the procedures for parole applications and decisions. The Commonwealth Parole Board (Consequential and Transitional Provisions) Act 2026, on the other hand, deals with the transitional and consequential issues arising from the implementation of the Commonwealth Parole Board Act 2026, ensuring a smooth transition from previous parole arrangements to the new system established by the Act.

Key Provisions

The Commonwealth Parole Board Act 2026 (section 3) establishes the Commonwealth Parole Board, an independent body responsible for making decisions about the release of prisoners on parole. The Act also specifies the procedures for parole applications, including the criteria for parole eligibility and the process for conducting parole hearings (section 5). Additionally, the Act outlines the rights and obligations of parolees, including the requirement to comply with parole conditions (section 7). Under the Commonwealth Parole Board (Consequential and Transitional Provisions) Act 2026 (section 4), there are specific obligations imposed on the Commonwealth Parole Board and other relevant entities. These obligations include ensuring that the procedures and decisions of the Board comply with the Act, maintaining records of parole decisions, and providing information to the relevant authorities as required (section 6). The Act also outlines transitional provisions for the establishment of the Board, including the appointment of initial members and the transfer of existing parole functions to the Board (section 8). Breaching the provisions of the Commonwealth Parole Board Act 2026 or the Commonwealth Parole Board (Consequential and Transitional Provisions) Act 2026 can result in civil or criminal penalties. For example, section 12 of the Parole Board Act provides that any person who wilfully obstructs or interferes with the functions or operations of the Board commits an offence and is liable to a fine not exceeding $10,000 or imprisonment for a term not exceeding two years, or both. Similarly, section 9 of the Consequential and Transitional Provisions Act provides that any person who fails to comply with a requirement or direction of the Board commits an offence and is liable to a fine not exceeding $5,000. The National Health Amendment (Passive Immunological Products) Act 2026 (section 3) amends the National Health Act 1953 to include passive immunological products within the scope of the Act, ensuring that these products are subject to the same regulatory requirements as other medicines. This includes requirements for registration, quality control, and advertising (section 5). The Act also imposes obligations on manufacturers and importers of passive immunological products to ensure that they comply with these requirements (section 7). Under the Treasury Laws Amendment (Genetic Testing Protections in Life Insurance and Other Measures) Act 2026 (section 4), there are specific obligations imposed on life insurers and financial institutions. These obligations include prohibiting the use of genetic test results in assessing an individual's eligibility for life insurance or determining the terms of a financial product (section 6). The Act also imposes obligations on these entities to ensure that they comply with the Act's requirements for handling and storing genetic information (section 8). Breaching the provisions of the Act can result in civil or criminal penalties, including fines and imprisonment (section 10).